Project GRF 007 |GF-I (ng/ml) serum concentrations following repeated injections of GRF's analogs (hGRF(1-29) NH2)

TABLE 1


reatment (ΒΙD, 20 μg/kg SC)	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6
		-				
Saline	216 ±33	241 + 33	251 + 31	262 + 43	284 ± 24	744 - 57
(hours, 1) Land (1, 00)		20 1 1 1	101		204 E 31	Z44 ± 3/
(115,411,00GKF (1-29)NH2	227 ± 16	253 ±22	306 ± 30 ^a	306 ± 30 a 322 ± 28 a	334 + 29 a,b 309 + 29	309 + 29 a
						200 ± 20
(hexenov) trans 2) bons (1						
197 ± 20	197 ± 20	225 ± 16	271 ± 16 a	319 + 22 a.b	325 + 29 a,b	319 + 22 a.b 325 + 29 a.b 294 + 21 a.b
(hexenov trans_2) hope/1 2001mr		ŀ			020 2 CO	207 2 2 1
	- 23 / NA2 222 ± 22	299 ± 30	357 ± 43 a	373 + 36 8,6 341 + 22 8 370 + 38 8,6	341 + 22 B	370 + 38 8,b
					2112	210 7 00

a = P < 0.05 when compared to day 1 b = P < 0.05 when compared to day 2 Day 1 = Pretreatment

Treatment P=0.18

Days P< 0.0001

Treatment x Days P < 0.0001






TABLE 2

Treatment (BID, 20 μg/kg, SC)	Day 1 Pretreatment	Day 2	Day 3	Day 4	Day 5
	ng/ml	ng/ml	ng/ml	ng/ml	ng/ml
hGRF(1-29)NH2	252 ± 28	235 ± 19	263 ± 16	258 ± 17	262 ± 24
(Octanoyl) hGRF(1-29)NH2	316 ± 22	.287 ± 20	301 ±37	301 ± 37	318 ± 39
(Hexanoyl) hGRF(1-29)NH2	248 ± 20	281 ± 28	299 ± 26	319 ± 22ª	342 ± 21 a,b
(Butyryl) hGRF(1-29)NH2	278 ± 20	281 ± 24	302 ± 26	289 ± 26	293 ± 23

Treatment P= 0.42 Day P = 0.0004 Treatment x Day P= 0.011 a = P < 0.05 when compared to day 1 b = P < 0.05 when compared to day2